1. Home
  2. MIRM

MIRM

Mirum Pharmaceuticals Inc.

Logo Mirum Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Founded: 2018 Country:
United States
United States
Employees: N/A City: FOSTER CITY
Market Cap: 1.2B IPO Year: 2019
Target Price: $54.00 AVG Volume (30 days): 543.3K
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.00 EPS Growth: N/A
52 Week Low/High: $24.23 - $35.56 Next Earning Date: 05-02-2024
Revenue: $186,374,000 Revenue Growth: 141.85%
Revenue Growth (this year): 73.45% Revenue Growth (next year): 33.31%

Share on Social Networks: